Across the biopharma industry, conversations about manufacturing improvement often focus on digital transformation, artificial intelligence (AI), automation, observability, interoperability, process intensification, and productivity. These initiatives are all important, but they share a common dependency, reliability.
Reliability is often assumed rather than discussed. Yet equipment failures can undermine bioprocess performance, affecting yields, quality, and efficiency. Unplanned downtime can delay batch release, trigger deviation investigations, and disrupt broader digital transformation initiatives. As manufacturing becomes increasingly connected and data-driven, the ability to identify emerging issues early and intervene proactively is becoming just as important as the equipment itself. Organizations that continue to rely primarily on reactive maintenance approaches may find themselves at a growing competitive disadvantage.
Processes that experience frequent disruptions and inconsistent outcomes will also struggle to realize the full value of any digital, automation, or data-driven initiative. Digital transformation can improve visibility and decision-making, but it cannot compensate for unstable operations. For example, AI cannot predict what it cannot trust. Digital twins cannot accurately model unstable systems. Advanced analytics cannot create value from inconsistent operations. Reliability is not only the cornerstone of bioprocessing performance—it is the operational foundation upon which every digital initiative depends.
Why bioprocess equipment reliability matters more than ever
Historically, manufacturers could often absorb the impact of equipment failures through excess capacity, additional labor, or schedule flexibility. That margin for error is rapidly disappearing. Today's manufacturing environments are more complex, production schedules are tighter, and pressure on productivity continues to increase. New therapeutic modalities, accelerated development timelines, and rising operating costs mean that even minor disruptions can have a disproportionate impact on performance. Unplanned downtime ultimately impacts drug approval and getting therapies to patients who need them.
Biopharma is increasingly approaching an inflection point. As margins come under pressure, manufacturing complexity increases, and organizations look to maximize the return from existing assets, reliability is becoming a strategic business priority rather than simply a maintenance consideration. In an industry focused on productivity and reducing the cost of goods manufactured, digital transformation can help enable this. However, without reliable operations, continuous uptime may become the limiting factor between ambition and execution.
Moving from reactive to predictive maintenance in biomanufacturing
Historically, many manufacturing organizations have relied on preventative maintenance schedules and reactive interventions to manage equipment performance. Equipment is serviced at predetermined intervals and issues are addressed when failures occur.
While these approaches remain important, they are becoming increasingly difficult to sustain as operations become more complex, productivity expectations increase, and engineering resources become harder to secure. Across industries, maintenance strategies are evolving from reactive and time-based approaches toward condition-based and predictive models that use equipment data to identify emerging issues before operational performance is affected.
I witnessed this first-hand within the industrial gases industry. Historically, service intervals were largely determined by equipment age and fixed maintenance schedules. Over time, we recognized that age alone was not the best predictor of failure. Equipment utilization, operating conditions, and duty cycles had just as much influence on reliability and performance.
As condition monitoring and sensor technologies became more widely adopted, we gained the ability to assess the health of critical components in real time. Maintenance decisions could then be based on how equipment was performing rather than solely on predetermined service intervals. Assets operating under demanding conditions could be serviced more frequently, while equipment experiencing lower utilization could safely operate for longer between interventions. This predictive approach reduced unplanned downtime, increased equipment availability, and enabled more effective use of scarce engineering resources.
Perhaps as importantly, it created opportunities beyond reliability itself. As confidence in predicting equipment performance increased, organizations could gradually reduce some of the operational redundancy traditionally built into systems to protect against unexpected failures. Greater predictability enabled more efficient asset utilization, lower operating costs, and ultimately a more cost-effective model for delivering products and services.
Biopharma is increasingly moving in a similar direction. As connected equipment, condition monitoring, and data-driven insights become more widely adopted, manufacturers have an opportunity to shift reliability from a reactive activity to a proactive capability—preventing failure before it occurs. This is especially important in the biomanufacturing space, where unplanned downtime could result in batch failure, regulatory scrutiny, and delays in getting life-saving drug to patients in need, on time.
AI-driven maintenance for bioprocess equipment: Reliability starts with observability
Bioprocess observability is crucial for process understanding. However, reliable process understanding depends upon reliable operations. Sensors must perform consistently. Equipment must behave predictably. Data must be accurate and trustworthy. If asset performance fluctuates unexpectedly, understanding the true state of a process becomes significantly more difficult.
This can create a ripple effect across the organization. Root-cause investigations become more complex, deviations take longer to resolve, and opportunities for optimization become harder to identify. Reliable decisions depend on reliable data, and reliable data depends on reliable operations. Improving reliability therefore requires more than preventative maintenance schedules and reactive interventions. Organizations must first understand how equipment is performing, when performance begins to deteriorate, and where operational risks are emerging. As connected equipment and AI-driven monitoring technologies become more widely adopted, manufacturers are gaining greater visibility into asset health and system performance. That visibility is creating opportunities to move from reactive responses towards more proactive reliability strategies.
AI-enabled predictive maintenance uses continuous equipment data to identify early warning signs of stress that might cause downtime, often days or weeks before a failure occurs. Where preventive maintenance fixes machines on a planned schedule, predictive maintenance uses data, analytics, and AI to anticipate failures before they occur. By engaging with predicted risk instead of reacting to failures or scheduling maintenance, manufacturers can most effectively reduce unplanned downtime in bioprocessing.
Digital transformation depends on reliability, and vice versa
Many digital initiatives are built on the assumption that manufacturing systems are operating consistently. Analytics platforms, AI, digital twins, and predictive tools all depend on high-quality operational data. When equipment performs inconsistently or data becomes unreliable, the value of these digital technologies is reduced. In many cases, digital transformation does not eliminate reliability challenges—it exposes them. As organizations become more connected, issues such as recurring failures, poor asset utilization, and process variability become increasingly visible.
For instance, implementing AI-enabled predictive monitoring starts with identifying crucial equipment in your manufacturing workflow. Then, integrating automation and digital technologies, like sensors and plug-and-play device connectivity for bioprocess systems, becomes the foundation for integrated automation platform reliability. Modern manufacturing execution systems (MES) or automation systems, including offerings by companies like Cytiva, can often integrate equipment data into a unified platform.
This visibility is valuable, but it also reinforces a fundamental reality: organizations cannot optimize instability. Digital transformation does not create reliability, it depends upon it.
Bioprocess equipment reliability can become your competitive advantage
Historically, reliability in bioprocessing was often viewed as a maintenance objective. Increasingly, it is becoming a business objective. The ability to predict failures, maximize asset utilization, and operate consistently at scale directly influences productivity, efficiency, and manufacturing performance. Organizations that develop these capabilities gain more than improved uptime. They create a stronger foundation for growth, innovation, and digital transformation.
An interesting question for manufacturers to consider is this: As predictive service models become more common, will suppliers be evaluated not only on equipment performance, but also on their ability to deliver operational reliability throughout the asset lifecycle? Organizations may soon find themselves evaluating not only the equipment they buy, but also how effectively their suppliers help prevent failures before they occur.
From bioprocess performance to manufacturing predictability
The industry's focus on digital transformation, AI, and productivity is understandable. These initiatives have the potential to reshape how therapies are developed and manufactured. However, none of them can compensate for unreliable operations. The organizations that outperform will not necessarily be those investing in the most technology. They will be the ones capable of operating consistently, predictably, and reliably while adapting to increasing complexity and performance expectations.
Reliability is no longer just about keeping equipment running. It is about creating the predictability that modern manufacturing depends upon.
Reliability and the shift toward model-driven manufacturing
Reliability creates the foundation for better decisions, but the future of manufacturing will increasingly depend on how effectively organizations use data to make those decisions. The future of reliability is not fixing failures faster. It is preventing failures from occurring in the first place. In fact, model-driven manufacturing is already helping organizations move from reactive decision-making toward predictive and adaptive operations.